Moss, 11 February 2026

Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic
tests, today announced its results for the fourth quarter of 2025.

Highlights include:
Record sales of NOK 46.6 million in 4Q25, up 9% vs 4Q24 (12% organic growth).
Full year 2025 sales of NOK 176.5 million up 16% (17% organic growth) vs 2024. 

EBITDA of NOK 10.5 million in 4Q25 vs NOK 8.1 million in 4Q24. For the full year
of 2025 the EBITDA was NOK 34.6 million vs 24.7 million in 2024 (+40%). The
EBITDA for 2025 includes NOK 13.3 million (NOK 12 million) in pipeline
development expenses. 

Improved gross margin to 58% (56%) in 4Q25 and to 56% in 2025 versus 54% in
2024.  

Sales of Cystatin C increased with 22% in 4Q25 compared to 4Q24, and by 32% for
the full year 2025 versus 2024, driven by strong performance in the US. 
  
Sales of fCAL turbo decreased with 6% in 4Q25 compared to 4Q24, and by 1% for
the full year 2025 versus 2024, due to unusual high stock building in 4Q24.
 
Sales to the US were NOK 29.4 million in 2025 vs NOK 12.2 million in 2024. New
accounts and growth in existing accounts both contributed to increased revenues.
The warehouse shift for one of our largest customers accounts for about NOK 11.3
million of the 2025 revenue.
	
Very recent testing shows that the current assay version of NT-proBNP does not
perform reliably in the lower measurement range. The company has therefore
initiated activities to investigate whether redesigning the assay could improve
robustness, with initial results to be shared once available. The company
expects to present revised development timelines during Q2 2026.

Gentian announced an exclusive partnership with a top global diagnostics company
to develop a new assay that will be incorporated into one of the world's most
widely used clinical chemistry analyser platforms. 

The board proposes a dividend of NOK 0.60 per share based on a solid cash
position and sound underlying earnings with current growth opportunities fully
financed.  

Webcast 
The company will present the results today at 09.00 am, followed by a Q&A
session. The presentation will be held as a live webcast on the company's
website: 

https://www.gentian.com/investor-relation/presentations

The webcast will also be available on the company website after the
presentation. 

IR contact:
Njaal Kind, CFO 
njaal.kind@gentian.no 
+47 919 06 525 (mobile)

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Ole Sørlie, Business
controller at Gentian Diagnostics ASA, on 11 February 2025 at 08:20 CET. 

About Gentian Diagnostics 
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for
better treatment decisions.  Gentian's expertise and focus lie within
immunoassays, specifically for infections, inflammation, kidney disease and
heart failure. By converting existing and clinically relevant biomarkers to the
most efficient, high-throughput analysers, the company contributes to saving
costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway,
serving the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, USA, and China. For more information, please
visit www.gentian.com.